Resmed director Farrell sells $520k in stock
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil prices dip after 5-day winning streak; set for weekly surge on Iran conflict Trump replaces Homeland Security chief Kristi Noem Wall Street ends lower on escalating Iran conflict, report of AI export curbs Trump says he must be involved in selecting Iran’s next leader (South Africa Philippines Nigeria) Resmed director Farrell sells $520k in stock By Insider Trading Published 03/06/2026, 12:10 AM Resmed director Farrell sells $520k in stock 0 RMD -1.44% Director Peter C. Farrell of ResMed Inc (NYSE:RMD) sold 2,000 shares of the company’s common stock on March 4, 2026, for $260.22, totaling $520,440. The sale price came at a premium to the current stock price of $255.32, with the $37.19 billion medical device company trading below its InvestingPro Fair Value, suggesting the stock may be undervalued at current levels. Following the transaction, Farrell directly owns 62,773 shares of ResMed . The sale was executed under a Rule 10b5-1 plan adopted on August 12, 2025. An InvestingPro tip notes that management has been aggressively buying back shares, while the company has raised its dividend for 14 consecutive years. For deeper insights into RMD’s valuation and performance, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities. In other recent news, ResMed has reported its second-quarter fiscal 2026 financial results, which included an earnings per share of $2.81, surpassing analysts’ forecast of $2.73. The company’s revenue matched expectations at $1.4 billion. RBC Capital raised its price target for ResMed to $314 from $311, citing strong double-digit revenue and earnings growth that slightly exceeded both RBC and consensus estimates. KeyBanc Capital Markets also adjusted its price target for ResMed, increasing it to $302 from $299, based on what it described as "largely positive" financial results. Needham maintained its Hold rating on ResMed, noting an i...
Read full article at source